Extended HPV genotyping by the BD Onclarity assay: concordance with screening HPV-DNA assays, triage biomarkers, and histopathology in women from the NTCC2 study
Microbiology Spectrum · 07.01.2025 · 13 (1)
DOI: 10.1128/spectrum.00897-24 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Microbiology Spectrum, erschienen am 07.01.2025. Verfasst von Laura De Marco und 20 weiteren Autor:innen. Beteiligte Einrichtung: Center for Cervical Cancer Screening, City of Health and Science Hospital, Turin, Italy. Hauptthemen laut MEDLINE: DNA, Viral, Early Detection of Cancer, Genotype, Papillomaviridae. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero della Salute (Italy Ministry of Health).
Abstract (Originalsprache)
The use of clinically validated human papillomavirus (HPV) assays is recommended in cervical cancer screening, and extended genotyping is getting attention as a triage biomarker because of the different oncogenic risk of the high-risk HPV genotypes. We compared the results of the Becton & Dickinson (BD) Onclarity HPV assay, on the residual baseline cervico-vaginal specimens of the NTCC2 trial, to those of the screening HPV-DNA assay (Cobas 4800 or HC2) and to cytology, p16/ki67 and E6/E7 mRNA triage results. We genotyped virtually all HPV-positive women and a consecutive sample of HPV-negatives. Among the 3,129 baseline-positives, 75.5% ( k = 0.368) were BD-positive, as were 5 of the 333 baseline-negatives (1.5%). The concordance between BD and HPV-DNA screening test was 87% for Cobas (1,250/1,436) and 65.9% for HC2 (1,115/1,693). A higher than the recommended positivity threshold for Onclarity would increase the agreement but would not improve concordance in the overall screening population. Among the baseline-positive cases, we observed an increasing trend of BD positivity with cytology severity (from 71.6% in negative for intraepithelial lesion of malignancy to 95.1% in ASC-H+ samples), with histologically confirmed CIN3 (96.9%), with p16/ki67 dual staining positivity (90.9% among the positive and 69.6% among the negative specimens), and with E6/E7 mRNA positivity (93.4% in the mRNA-positive cases vs 39.7% among the mRNA-negatives). Our findings confirm some disagreement among different HPV assays used for screening. Nevertheless, the agreement is substantial for women with high-grade cytology, histologically confirmed CIN3, and p16/ki67 or mRNA positivity at triage, thus confirming a good clinical performance of all the tests used. The NTCC2 trial is registered as Clinicaltrials.gov identifier NCT01837693 . IMPORTANCE Large randomized clinical trials have demonstrated that human papillomavirus (HPV) testing for high-risk types is more effective than cytology in detecting pre-cancerous lesions and preventing cervical cancer. Its use is being implemented in cervical cancer screening in several countries. The most recent guidelines recommend a risk-based management. It is therefore important to assess the individual risk of having/developing high-grade lesions of women testing high-risk HPV-positive. A crucial viral factor influencing the risk is the HPV genotype since different types are associated to different carcinogenetic risks. Understanding the degree of concordance among different assays targeting either HPV presence/type(s) or cellular morphology and proteins’ expression provides knowledge useful to better define how these tests can be used in screening protocols for an effective triage and to anticipate the possible implementation issues. Our study shows that the concordance between tests is higher when the infections have a higher probability of producing a clinically relevant lesion.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Cervical Cancer Screening, City of Health and Science Hospital, Turin, Italy.
- Unit of Cancer Epidemiology and Center for Cancer Prevention (CPO), City of Health and Science Hospital, Turin, Italy.
- Institute for Cancer Research, Prevention and Oncological Network (ISPRO), Florence, Italy.
- Center for Cancer Epidemiology and Prevention (CPO), Turin, Italy.
- Epidemiology Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
- Laboratorio Unico di Screening, USL Umbria 1, Perugia, Italy.
ORCID-Profile: Laura De Marco, Simonetta Bisanzi, Annarosa Del Mistro, Paolo Giorgi Rossi, Maria Benevolo
Förderung
- Ministero della Salute (Italy Ministry of Health)
Zitieren
APA
De Marco, L., Bisanzi, S., Ronco, G., Mancuso, P., Carozzi, F., Allia, E., Rizzolo, R., Gustinucci, D., Frayle, H., Viti, J., Iossa, A., Cesarini, E., Bulletti, S., Passamonti, B., Gori, S., Toniolo, L., Venturelli, F., Del Mistro, A., Giorgi Rossi, P., …, & NTCC2 Working Group (2025). Extended HPV genotyping by the BD Onclarity assay: concordance with screening HPV-DNA assays, triage biomarkers, and histopathology in women from the NTCC2 study. Microbiology Spectrum, 13(1). https://doi.org/10.1128/spectrum.00897-24
Vancouver
De Marco L, Bisanzi S, Ronco G, Mancuso P, Carozzi F, Allia E, et al. Extended HPV genotyping by the BD Onclarity assay: concordance with screening HPV-DNA assays, triage biomarkers, and histopathology in women from the NTCC2 study. Microbiology Spectrum. 2025;13(1). doi:10.1128/spectrum.00897-24
BibTeX
@article{DeMarco2025,
author = {De Marco, Laura and Bisanzi, Simonetta and Ronco, Guglielmo and Mancuso, Pamela and Carozzi, Francesca and Allia, Elena and Rizzolo, Raffaella and Gustinucci, Daniela and Frayle, Helena and Viti, Jessica and Iossa, Anna and Cesarini, Elena and Bulletti, Simonetta and Passamonti, Basilio and Gori, Silvia and Toniolo, Laura and Venturelli, Francesco and Del Mistro, Annarosa and Giorgi Rossi, Paolo and Benevolo, Maria and NTCC2 Working Group, NTCC2 Working Group},
title = {Extended HPV genotyping by the BD Onclarity assay: concordance with screening HPV-DNA assays, triage biomarkers, and histopathology in women from the NTCC2 study},
journal = {Microbiology Spectrum},
year = {2025},
volume = {13},
number = {1},
doi = {10.1128/spectrum.00897-24}
}
EUVIMED